Of special interest, a combination of CPI0610 with the IMiDs lenalidomide and pomalidomide showed also in vitro synergism, involving the inhibition of the IKZF1/IRF4/MYC signaling axis [72] and warranting the clinical evaluation of this combination strategy in MM patients. Here, MYC is linked to Miyoshi myopathy.